KMDA Long Call Strategy

KMDA (Kamada Ltd.), in the Healthcare sector, (Drug Manufacturers - Specialty & Generic industry), listed on NASDAQ.

Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD. It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN for Allergic rhinitis and Urticaria; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for cytomegalovirus virus; RUCONEST for angioedema attacks; heparin sodium injection for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. Further, it offers IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis ; and ELIGARD for prostate cancer.

KMDA (Kamada Ltd.) trades in the Healthcare sector, specifically Drug Manufacturers - Specialty & Generic, with a market capitalization of approximately $453.4M, a trailing P/E of 22.37, a beta of 0.20 versus the broader market, a 52-week range of 6.5-9.35, average daily share volume of 60K, a public-listing history dating back to 2013, approximately 420 full-time employees. These structural characteristics shape how KMDA stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 0.20 indicates KMDA has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure. KMDA pays a dividend, which adjusts put-call parity and shifts the ex-dividend pricing across the listed chain.

What is a long call on KMDA?

A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration.

Current KMDA snapshot

As of May 15, 2026, spot at $7.76, ATM IV 96.40%, IV rank 26.07%, expected move 27.64%. The long call on KMDA below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.

Why this long call structure on KMDA specifically: KMDA IV at 96.40% is on the cheap side of its 1-year range, which favors premium-buying structures like a KMDA long call, with a market-implied 1-standard-deviation move of approximately 27.64% (roughly $2.14 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated KMDA expiries trade a higher absolute premium for lower per-day decay. Position sizing on KMDA should anchor to the underlying notional of $7.76 per share and to the trader's directional view on KMDA stock.

KMDA long call setup

The KMDA long call below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With KMDA near $7.76, the first option leg uses a $7.76 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed KMDA chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 KMDA shares for the stock leg in covered calls and collars).

ActionTypeStrike / BasisPremium (est)
Buy 1Call$7.76N/A

KMDA long call risk and reward

Net Premium / Debit
N/A
Max Profit (per contract)
Unbounded
Max Loss (per contract)
Unbounded
Breakeven(s)
None on modeled curve
Risk / Reward Ratio
N/A

Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium.

KMDA long call payoff curve

Modeled P&L at expiration across a range of underlying prices for the long call on KMDA. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

When traders use long call on KMDA

Long calls on KMDA express a bullish thesis with defined risk; traders use them ahead of KMDA catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.

KMDA thesis for this long call

The market-implied 1-standard-deviation range for KMDA extends from approximately $5.62 on the downside to $9.90 on the upside. A KMDA long call expresses a directional view that the underlying closes above the strike plus premium at expiration, ideally with implied volatility holding or expanding to preserve extrinsic value through the hold period. Current KMDA IV rank near 26.07% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on KMDA at 96.40%. As a Healthcare name, KMDA options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to KMDA-specific events.

KMDA long call positions are structurally bullish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. KMDA positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move KMDA alongside the broader basket even when KMDA-specific fundamentals are unchanged. Long-premium structures like a long call on KMDA are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current KMDA chain quotes before placing a trade.

Frequently asked questions

What is a long call on KMDA?
A long call on KMDA is the long call strategy applied to KMDA (stock). The strategy is structurally bullish: A long call buys upside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes above the strike plus premium at expiration. With KMDA stock trading near $7.76, the strikes shown on this page are snapped to the nearest listed KMDA chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are KMDA long call max profit and max loss calculated?
Max profit is unbounded; max loss equals the premium paid times 100. Breakeven is strike plus premium. For the KMDA long call priced from the end-of-day chain at a 30-day expiry (ATM IV 96.40%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a KMDA long call?
The breakeven for the KMDA long call priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current KMDA market-implied 1-standard-deviation expected move is approximately 27.64%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a long call on KMDA?
Long calls on KMDA express a bullish thesis with defined risk; traders use them ahead of KMDA catalysts (earnings, product launches, macro events) when the expected upside justifies the premium and theta decay.
How does current KMDA implied volatility affect this long call?
KMDA ATM IV is at 96.40% with IV rank near 26.07%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.

Related KMDA analysis